Molecular Therapy — Nucleic AcidsCancer BiologyPeer-reviewed journal article
miR-21: A therapeutic target for delaying severe liver disease and hepatocellular carcinoma in high-fat-diet-fed mice
Urmila JagtapiD, Anan Quan, Yuho OnoiD, Jonathan D. LeeiD, Alice Cristina RodriguesiD, Kylie A. SheniD, Sergei A. Manakov, Gyöngyi SzabóiD, Imad Ahmad NasseriD, Frank John SlackiD
Abstract
Liver disease, including hepatocellular carcinoma (HCC), is a major global health concern, claiming approximately 2 million lives worldwide annually, yet curative treatments remain elusive. In this study, we aimed to investigate the role of microRNA-21-5p (miR-21) in metabolic dysfunction-associated steatotic liver disease (previously NAFLD), metabolic-associated steatohepatitis (previously NASH), and HCC within the context of a Western high-fat diet, without additional choline (HFD) and offering potential therapeutic insights. We found that reduced miR-21 levels correlated with liver disease progression in WT mice fed on HFD, while miR-21 knockout mice showed exacerbated metabolic dysfunction, including obesity, hepatomegaly, hyperglycemia, insulin resistance, steatosis, fibrosis, and HCC. Our study reveals that miR-21 plays a protective role in metabolic syndrome and in the progression of liver disease to cancer. MiR-21 directly targets Transforming growth factor beta-induced (Tgfbi), a gene also known to be significantly upregulated and a potential oncogene in HCC. Further, our study showed that intervention with the administration of a miR-21 mimic in WT livers effectively improves insulin sensitivity, steatosis, fibrosis, Tgfbi expression and tumor burden in HFD conditions. These findings indicate that miR-21 could serve as an effective strategy to delay or prevent liver disease in high-fat-diet environments. SignificanceOur study demonstrates in vivo that miR-21 has protective functions in the broad spectrum of high-fat diet-based, progressive liver disease and cancer, and we show potential therapeutic value of a microRNA-21 mimic. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=137 SRC="FIGDIR/small/613915v2_ufig1.gif" ALT="Figure 1"> View larger version (51K): org.highwire.dtl.DTLVardef@1915cd8org.highwire.dtl.DTLVardef@66887corg.highwire.dtl.DTLVardef@18a8e54org.highwire.dtl.DTLVardef@18631b0_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: mouse
- research focus: host-pathogen & immune response
- research focus: cancer & tumor microenvironment
- research focus: metabolism & bioenergetics
- approach: experimental assay
- Citations
- 7
- FWCI
- 2.26
- Field percentile
- top 11%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- microRNA-21 promotes dysregulated lipid metabolism and hepatocellular carcinoma
Chad Hilton Vansant-Webb, Jessye C. Castro, … Kimberley Jane Evason·Disease Models & MechanismsPeer-reviewed·Jan 26, 2026
- HypoxamicroRNA-210 protects against hepatic steatosis by inhibiting CIDEC expression
Bo Yan, Sonia C. Youhanna, … Sergiu‐Bogdan Catrina·bioRxiv·Dec 20, 2025
- Hepatocyte-specific miR-33 deletion attenuates NAFLD-NASH-HCC progression
P. FERNANDEZ TUSSY, J. Sun, … C. Fernandez-Hernando·bioRxiv·Jan 18, 2023
- Hepatocyte-specific activity of TSC22D4 triggers progressive NAFLD by impairing mitochondrial function
G. Wolff, M. Sakurai, … S. Herzig·bioRxiv·Dec 17, 2021
- FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis
C. Liu, M. Schönke, … P. C. Rensen·bioRxiv·Sep 20, 2022
- Role of Mcpip1 in obesity-induced hepatic steatosis as determined by myeloid and liver-specific conditional knockouts.
Natalia Pydyn, Dariusz Żurawek, … Jerzy Kotlinowski·FEBS JournalPeer-reviewed·May 31, 2021